Home / Business and Economy / Longeveron Shares Plummet After Trial Setback
Longeveron Shares Plummet After Trial Setback
17 Sep
Summary
- Longeveron is exploring strategic options following a trial failure.
- Experimental stem cell therapy did not meet primary goals in a mid-stage trial.
- Company shares dropped nearly 60% after the announcement on Wednesday.
Longeveron announced on Wednesday that it is initiating a review of strategic alternatives. This decision follows the disappointing outcome of a mid-stage clinical trial for its experimental stem cell therapy, designed to treat a rare heart condition in infants.
The therapy failed to achieve its primary endpoint in the trial. This critical setback led to a significant market reaction. Shares of Longeveron, which had previously appreciated by 32% this year, experienced a sharp decline, dropping nearly 60% in after-hours trading immediately following the announcement.
The company's leadership will now evaluate various strategic pathways to address the implications of the trial results. Further updates regarding the company's strategic direction are anticipated.
